Lab-quality
accuracy
Designed for precise,
quantitative results.
See your insulin.
Understand your metabolism.
insi is the at-home insulin measurement system being developed by Insara to help make fasting and post-meal insulin visible, understandable and actionable.
▸ COMING 2028 • PATENT PENDING
ⓘ Coming 2028. insi is currently in development and is not FDA cleared. Not available for sale. Patent pending.
Designed for precise,
quantitative results.
Syncs securely with
the Insara app.
A small sample.
Powerful insight.
Insulin can become elevated long before glucose or A1c changes. Yet today, it is difficult to measure repeatedly outside of a laboratory.
That’s the gap insi is being built to fill.
insi times the assay and captures the quantitative result.
Insara makes insulin visible, understandable, and actionable—so women can take control of their metabolic and reproductive health.
A world where insulin is measured, understood, and managed—at home.
Where testing and lowering insulin has
the most potential impact.
PCOS/PMOS and infertility
Perimenopause and
general metabolic wellness
Built For
The same reading means something different depending on who’s looking at it.
For Patients
insi is launching where insulin resistance shows up earliest and matters most — polycystic ovary syndrome and unexplained infertility. More of reproductive health is on the roadmap.
Test at home, on your own timeline — no appointment, no waiting room.
See your insulin at rest and after you eat — not just one number.
Every reading plots in the Insara app, sharpening your insights over time.
For Healthcare Providers
Patients arrive with weeks of fasting and post-meal readings instead of a single office draw — across a 3–300 µIU/mL, CLIA-certified range you can act on.
Fasting and post-meal insulin trends between visits, not a single fasting draw.
Exportable history your patients can bring straight into the chart.
Built on CLIA-certified assay technology you can stand behind.
For Healthcare Providers
Patients arrive with weeks of fasting and post-meal readings instead of a single office draw — across a 3–300 µIU/mL, CLIA-certified range you can act on.
Fasting and post-meal insulin trends between visits, not a single fasting draw.
Exportable history your patients can bring straight into the chart.
Built on CLIA-certified assay technology you can stand behind.
Why It Matters
Understanding how food affects your insulin response helps you make better choices. That’s the beauty of insi — making the invisible visible, understandable, and actionable, so you can build a Low Insulin Lifestyle and reverse insulin resistance.
Be the first to know when insi is available. We’ll only email you about insi.
Both your fasting insulin and your post-meal insulin response, from a single drop of blood each time, across a 3–300 µIU/mL range. Insulin resistance is one of the earliest, most actionable signals in PCOS and infertility, often shifting years before glucose does.
It’s Insara’s approach to turning your own fasting and post-meal readings into real food and lifestyle choices — making an invisible number visible, understandable, and actionable, so you can lower your insulin over time and work toward reversing insulin resistance.
insi runs on CLIA-certified assay technology — the same accuracy standard used in clinical labs — built into a reader small enough for your kitchen counter.
No. Insert the cassette and insi starts its own timer, reading the result automatically once the assay is ready — no stopwatch, no premature reads.
insi is intended as a personal insight and monitoring tool, not a substitute for diagnosis or treatment. It is still in development: FDA clearance and our device patent are both pending, and insi is not yet available for purchase. Always loop in your healthcare provider on results that concern you.
Every reading syncs automatically over Bluetooth to the Insara app, where it’s plotted against your target range and your history.
insi is still in development and not yet available — FDA clearance and our patent are both pending. Join the waitlist below and we’ll email you the moment early access opens, with early-access pricing.
Insulin resistance is central to both — it’s one of the most common drivers of PCOS and a frequently overlooked factor in unexplained infertility. Starting there lets Insara build the clearest possible picture before expanding to other stages of reproductive health.
Yes — select “Healthcare Provider” on the waitlist form below and our team will follow up directly.